{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:03:32Z","timestamp":1784563412198,"version":"3.55.0"},"reference-count":202,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract disease (LRTD) in infants and older adults worldwide. Although vaccines based on the fusion (F) protein have shown progress, their efficacy remains limited by antigenic instability and viral evolution. The metastable transition of the F protein between prefusion (preF) and postF conformations critically determines the exposure of neutralizing epitopes, with most potent antibodies targeting preF\u2013specific sites. In addition, the glycosylated G protein contributes to immune evasion through glycan shielding and CX3C-mediated immunomodulation. Recent advances in structural biology and computational protein design have improved the stabilization of preF conformations; however, these approaches do not fully address antigenic variability. Emerging methods, including protein language models (PLMs) and structure prediction frameworks, enable antigen design to be guided by sequence\u2013structure relationships, allowing researchers to prioritize candidate antigens with favorable stability profiles. Here, we propose the term \u201cRational Design 2.0\u201d to describe this emerging framework. By integrating structural information with evolutionary and sequence-level constraints, Rational Design 2.0 extends RSV vaccine design beyond static structural optimization and provides a conceptual framework for future vaccine-development strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1862216","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:31:33Z","timestamp":1782102693000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Rational design 2.0: transitioning from static structural biology to computational prioritization and iterative vaccine optimization for RSV"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiulong","family":"Wei","sequence":"first","affiliation":[{"name":"Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"Institute of Virology and Acquired Immunodeficiency Syndrome (AIDS) Research, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"Institute of Virology and Acquired Immunodeficiency Syndrome (AIDS) Research, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaolong","family":"Li","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"Institute of Virology and Acquired Immunodeficiency Syndrome (AIDS) Research, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.virusres.2011.09.020","article-title":"Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years","volume":"162","author":"Collins","year":"2011","journal-title":"Virus Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.865592","article-title":"Innate immune evasion by human respiratory syncytial virus","volume":"13","author":"Ouyang","year":"2022","journal-title":"Front Microbiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70373","article-title":"Disease burden of RSV infection in adult patients in comparison to influenza virus infection","volume":"97","author":"Trifonov","year":"2025","journal-title":"J Med Virol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01639-24","article-title":"Examination of respiratory syncytial virus fusion protein proteolytic processing and roles of the P27 domain","volume":"98","author":"Neal","year":"2024","journal-title":"J Virol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/v5010211","article-title":"Respiratory syncytial virus entry inhibitors targeting the F protein","volume":"5","author":"Sun","year":"2013","journal-title":"Viruses"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2369-7","article-title":"IGF1R is an entry receptor for respiratory syncytial virus","volume":"583","author":"Griffiths","year":"2020","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.5c00368","article-title":"Structural basis for postfusion-specific binding to the respiratory syncytial virus F protein by the canonical antigenic site I antibody 131\u20132a","volume":"11","author":"Peng","year":"2025","journal-title":"ACS Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F\u2013specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci Transl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13111133","article-title":"RSV vaccines: Targeting prefusion F and G proteins from structural design to clinical application","volume":"13","author":"Yu","year":"2025","journal-title":"Vaccines"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.3.1600","article-title":"Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses","volume":"176","author":"Harcourt","year":"2006","journal-title":"J Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01675","article-title":"Biology of infection and disease pathogenesis to guide RSV vaccine development","volume":"10","author":"Boyoglu-Barnum","year":"2019","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/v14020419","article-title":"How RSV proteins join forces to overcome the host innate immune response","volume":"14","author":"Van Royen","year":"2022","journal-title":"Viruses"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13081876","article-title":"Immunomodulation in respiratory syncytial virus infection: Mechanisms, therapeutic targets, and clinical implications","volume":"13","author":"Georgakopoulou","year":"2025","journal-title":"Microorganisms"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.332791","article-title":"The small hydrophobic protein of the human respiratory syncytial virus forms pentameric ion channels","volume":"287","author":"Gan","year":"2012","journal-title":"J Biol Chem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02717-06","article-title":"Function of the respiratory syncytial virus small hydrophobic protein","volume":"81","author":"Fuentes","year":"2007","journal-title":"J Virol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01070-15","article-title":"Partial attenuation of respiratory syncytial virus with a deletion of a small hydrophobic gene is associated with elevated interleukin-1\u03b2 responses","volume":"89","author":"Russell","year":"2015","journal-title":"J Virol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13916","article-title":"A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation","volume":"7","author":"Stobart","year":"2016","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00655-9","article-title":"Functional organization of cytoplasmic inclusion bodies in cells infected by respiratory syncytial virus","volume":"8","author":"Rincheval","year":"2017","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01202-20","article-title":"Minimal elements required for the formation of respiratory syncytial virus cytoplasmic inclusion bodies in vivo and in vitro","volume":"11","author":"Galloux","year":"2020","journal-title":"mBio"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01380-20","article-title":"Respiratory syncytial virus sequesters NF-\u03baB subunit p65 to cytoplasmic inclusion bodies to inhibit innate immune signaling","volume":"94","author":"Jobe","year":"2020","journal-title":"J Virol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-003-0112-y","article-title":"The matrix protein of human respiratory syncytial virus localises to the nucleus of infected cells and inhibits transcription","volume":"148","author":"Ghildyal","year":"2003","journal-title":"Arch Virol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00609-15","article-title":"Brief history and characterization of enhanced respiratory syncytial virus disease","volume":"23","author":"Acosta","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18081717","article-title":"Respiratory syncytial virus: The influence of serotype and genotype variability on clinical course of infection","volume":"18","author":"Vandini","year":"2017","journal-title":"IJMS"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd7331","article-title":"Learning the language of viral evolution and escape","volume":"371","author":"Hie","year":""},{"key":"B28","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","article-title":"Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus","volume":"176","author":"Marcandalli","year":"2019","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1829899","article-title":"A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults","volume":"17","author":"Aliprantis","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.47.1.171-177.1983","article-title":"Monoclonal antibodies to respiratory syncytial virus proteins: Identification of the fusion protein","volume":"47","author":"Walsh","year":"1983","journal-title":"J Virol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.151098198","article-title":"Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion","volume":"98","author":"Gonz\u00e1lez-Reyes","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2000.4093","article-title":"Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection","volume":"280","author":"Behera","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/v13020261","article-title":"Identification of RSV fusion protein interaction domains on the virus receptor, nucleolin","volume":"13","author":"Mastrangelo","year":"2021","journal-title":"Viruses"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005622","article-title":"EGFR interacts with the fusion protein of respiratory syncytial virus strain 2-20 and mediates infection and mucin expression","volume":"12","author":"Currier","year":"2016","journal-title":"PloS Pathog"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.858629","article-title":"Receptors for respiratory syncytial virus infection and host factors regulating the life cycle of respiratory syncytial virus","volume":"12","author":"Feng","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001951","article-title":"Mapping respiratory syncytial virus fusion protein interactions with the receptor IGF1R and the impact of alanine-scanning mutagenesis on viral infection","volume":"12","author":"Hayes","year":"2024","journal-title":"J Gen Virol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2444","article-title":"Identification of nucleolin as a cellular receptor for human respiratory syncytial virus","volume":"17","author":"Tayyari","year":"2011","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003309","article-title":"Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein","volume":"9","author":"Krzyzaniak","year":"2013","journal-title":"PloS Pathog"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01625-07","article-title":"Viral and host factors in human respiratory syncytial virus pathogenesis","volume":"82","author":"Collins","year":"2008","journal-title":"J Virol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-4-51","article-title":"Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps","volume":"4","author":"Ternette","year":"2007","journal-title":"Virol J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1101\/2024.08.02.606199","article-title":"Respiratory syncytial virus (RSV) optimizes the translational landscape during infection","author":"Kerkhofs","year":"2024","journal-title":"bioRxiv"},{"key":"B43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-642-38919-1_4","article-title":"Structure and function of RSV surface glycoproteins","volume":"372","author":"McLellan","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-01012-2","article-title":"Differences between RSV a and RSV B subgroups and implications for pharmaceutical preventive measures","volume":"13","author":"Nuttens","year":"2024","journal-title":"Infect Dis Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2015.04.005","article-title":"Novel antigens for RSV vaccines","volume":"35","author":"Graham","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175792","article-title":"Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV\/a and RSV\/B","volume":"12","author":"Hause","year":"2017","journal-title":"PloS One"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2015.03.002","article-title":"Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein","volume":"11","author":"McLellan","year":"2015","journal-title":"Curr Opin Virol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1106536108","article-title":"Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers","volume":"108","author":"Swanson","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00972.x","article-title":"Biological challenges and technological opportunities for respiratory syncytial virus vaccine development","volume":"239","author":"Graham","year":"2011","journal-title":"Immunol Rev"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12010097","article-title":"All eyes on the prefusion-stabilized F construct, but are we missing the potential of alternative targets for respiratory syncytial virus vaccine design","volume":"12","author":"Schaerlaekens","year":"2024","journal-title":"Vaccines"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1710895","article-title":"RSV vaccine development: Advances and fusion protein-focused strategies","volume":"17","author":"Xu","year":"2026","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/v14122702","article-title":"Neutralizing and epitope-specific antibodies against respiratory syncytial virus in maternal and cord blood paired samples","volume":"14","author":"Mashiyama","year":"2022","journal-title":"Viruses"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00706","article-title":"Antigenic site-specific competitive antibody responses to the fusion protein of respiratory syncytial virus were associated with viral clearance in hematopoietic cell transplantation adults","volume":"10","author":"Ye","year":"2019","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"10085","DOI":"10.1038\/s41467-024-54384-x","article-title":"A potent broad-spectrum neutralizing antibody targeting a conserved region of the prefusion RSV F protein","volume":"15","author":"Sun","year":"2024","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908380","article-title":"Respiratory syncytial virus vaccination during pregnancy and effects in infants","volume":"383","author":"Madhi","year":"2020","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105318","article-title":"The role of respiratory syncytial virus G protein in immune cell infection and pathogenesis","volume":"107","author":"Anderson","year":"2024","journal-title":"eBioMedicine"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/v13071214","article-title":"Functional features of the respiratory syncytial virus G protein","volume":"13","author":"Anderson","year":"2021","journal-title":"Viruses"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12070807","article-title":"The central conserved peptides of respiratory syncytial virus G protein enhance the immune response to the RSV F protein in an adenovirus vector vaccine candidate","volume":"12","author":"Chai","year":"2024","journal-title":"Vaccines"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.12.6164-6171.2002","article-title":"The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivo","volume":"76","author":"Teng","year":"2002","journal-title":"J Virol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s44298-024-00075-9","article-title":"Respiratory syncytial virus glycoprotein G impedes CX3CR1-activation by CX3CL1 and monocyte function","volume":"2","author":"Meineke","year":"2024","journal-title":"NPJ Viruses"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005318","article-title":"Respiratory syncytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures","volume":"11","author":"Johnson","year":"2015","journal-title":"PloS Pathog"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aar3534","article-title":"Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies","volume":"3","author":"Fedechkin","year":"2018","journal-title":"Sci Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1084139","article-title":"Immune escaping of the novel genotypes of human respiratory syncytial virus based on gene sequence variation","volume":"13","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032807","article-title":"Genetic variability of human respiratory syncytial virus a strains circulating in ontario: A novel genotype with a 72 nucleotide G gene duplication","volume":"7","author":"Eshaghi","year":"2012","journal-title":"PloS One"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s44298-026-00172-x","article-title":"The soluble G protein of respiratory syncytial virus promotes viral dissemination via TLR2-mediated NLRP3 priming and pyroptosis","volume":"4","author":"Meineke","year":"2026","journal-title":"NPJ Viruses"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.68.7.4538-4546.1994","article-title":"The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons","volume":"68","author":"Roberts","year":"1994","journal-title":"J Virol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25189800","article-title":"The role of the CX3CR1-CX3CL1 axis in respiratory syncytial virus infection and the triggered immune response","volume":"25","author":"Rivas-Fuentes","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01741-13","article-title":"Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses","volume":"87","author":"Chirkova","year":"2013","journal-title":"J Virol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01604-08","article-title":"The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on fc receptor-bearing leukocytes","volume":"82","author":"Bukreyev","year":"2008","journal-title":"J Virol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01162-12","article-title":"The secreted G protein of human respiratory syncytial virus antagonizes antibody-mediated restriction of replication involving macrophages and complement","volume":"86","author":"Bukreyev","year":"2012","journal-title":"J Virol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.70.11.7783-7791.1996","article-title":"Generation of atypical pulmonary inflammatory responses in BALB\/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus","volume":"70","author":"Hancock","year":"1996","journal-title":"J Virol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.4.2871-2880.1998","article-title":"Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge","volume":"72","author":"Johnson","year":"1998","journal-title":"J Virol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/intimm\/4.4.493","article-title":"Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G","volume":"4","author":"Openshaw","year":"1992","journal-title":"Int Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2020587118","article-title":"Structural basis for IFN antagonism by human respiratory syncytial virus nonstructural protein 2","volume":"118","author":"Pei","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00413-11","article-title":"Multiple functional domains and complexes of the two nonstructural proteins of human respiratory syncytial virus contribute to interferon suppression and cellular location","volume":"85","author":"Swedan","year":"2011","journal-title":"J Virol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00715-09","article-title":"Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways","volume":"83","author":"Swedan","year":"2009","journal-title":"J Virol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029386","article-title":"Respiratory syncytial virus NS1 protein colocalizes with mitochondrial antiviral signaling protein MAVS following infection","volume":"7","author":"Boyapalle","year":"2012","journal-title":"PloS One"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.67.1.227","article-title":"How cells respond to interferons","volume":"67","author":"Stark","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1395809","article-title":"Respiratory syncytial virus NS1 inhibits anti-viral interferon-\u03b1-induced JAK\/STAT signaling, by limiting the nuclear translocation of STAT1","volume":"15","author":"Efstathiou","year":"2024","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001336","article-title":"Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response","volume":"7","author":"Munir","year":"2011","journal-title":"PloS Pathog"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr9995","article-title":"Single-cell profiling demonstrates the combined effect of wheeze phenotype and infant viral infection on airway epithelial development","volume":"11","author":"Berdnikovs","year":"2025","journal-title":"Sci Adv"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.78.8.4363-4369.2004","article-title":"Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected","volume":"78","author":"Spann","year":"2004","journal-title":"J Virol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad281","article-title":"Evaluation of the live-attenuated intranasal respiratory syncytial virus (RSV) vaccine RSV\/6120\/\u0394NS2\/1030s in RSV-seronegative young children","volume":"229","author":"Karron","year":"2024","journal-title":"J Infect Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02769-12","article-title":"Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature","volume":"87","author":"Luongo","year":"2013","journal-title":"J Virol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.4.3438-3442.1999","article-title":"Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees","volume":"73","author":"Whitehead","year":"1999","journal-title":"J Virol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413275","article-title":"Activity of oral ALS-008176 in a respiratory syncytial virus challenge study","volume":"373","author":"DeVincenzo","year":"2015","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.21.10776-10784.2002","article-title":"The major phosphorylation sites of the respiratory syncytial virus phosphoprotein are dispensable for virus replication in vitro","volume":"76","author":"Lu","year":"2002","journal-title":"J Virol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.cell.2019.08.014","article-title":"Structure of the respiratory syncytial virus polymerase complex","volume":"179","author":"Gilman","year":"2019","journal-title":"Cell"},{"key":"B89","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-642-38919-1_1","article-title":"Respiratory syncytial virus: Virology, reverse genetics, and pathogenesis of disease","volume":"372","author":"Collins","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1014089","article-title":"Liquid-liquid phase separation mediated immune evasion of respiratory syncytial virus against oligoadenylate synthetase-RNase L pathway","volume":"22","author":"Hwang","year":"2026","journal-title":"PloS Pathog"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00215-12","article-title":"Human respiratory syncytial virus nucleoprotein and inclusion bodies antagonize the innate immune response mediated by MDA5 and MAVS","volume":"86","author":"Lifland","year":"2012","journal-title":"J Virol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/v13122449","article-title":"Interactions between the nucleoprotein and the phosphoprotein of pneumoviruses: Structural insight for rational design of antivirals","volume":"13","author":"Decool","year":"2021","journal-title":"Viruses"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.064931-0","article-title":"Recombinant bovine respiratory syncytial virus with deletion of the SH gene induces increased apoptosis and pro-inflammatory cytokines in vitro, and is attenuated and induces protective immunity in calves","volume":"95","author":"Taylor","year":"2014","journal-title":"J Gen Virol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00737-17","article-title":"Preclinical characterization of PC786, an inhaled small-molecule respiratory syncytial virus L protein polymerase inhibitor","volume":"61","author":"Coates","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B95","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/infdis\/jiz408","article-title":"Safety and immunogenicity of the respiratory syncytial virus vaccine RSV\/\u0394NS2\/\u03941313\/I1314L in RSV-seronegative children","volume":"222","author":"Karron","year":"2020","journal-title":"J Infect Dis"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.000855","article-title":"Modulation of the transcription factor NF-\u03baB in antigen-presenting cells by bovine respiratory syncytial virus small hydrophobic protein","volume":"98","author":"Pollock","year":"2017","journal-title":"J Gen Virol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02374-08","article-title":"The respiratory syncytial virus matrix protein possesses a Crm1-mediated nuclear export mechanism","volume":"83","author":"Ghildyal","year":"2009","journal-title":"J Virol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/v10100535","article-title":"Respiratory syncytial virus matrix (M) protein interacts with actin in vitro and in cell culture","volume":"10","author":"Shahriari","year":"2018","journal-title":"Viruses"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06744-11","article-title":"The human respiratory syncytial virus matrix protein is required for maturation of viral filaments","volume":"86","author":"Mitra","year":"2012","journal-title":"J Virol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03500-14","article-title":"Dimerization of matrix protein is required for budding of respiratory syncytial virus","volume":"89","author":"F\u00f6rster","year":"2015","journal-title":"J Virol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1101\/2023.03.13.532372","article-title":"Specific targeting and clustering of phosphatidylserine lipids by RSV M protein is critical for virus particle production","volume":"299","author":"Swain","year":"2023"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.198853","article-title":"Caveolae provide a specialized membrane environment for respiratory syncytial virus assembly","volume":"130","author":"Ludwig","year":"2017","journal-title":"J Cell Sci"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2013.07.010","article-title":"Human respiratory syncytial virus N, P and M protein interactions in HEK-293T cells","volume":"177","author":"Oliveira","year":"2013","journal-title":"Virus Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0712144105","article-title":"Respiratory syncytial virus uses a Vps4-independent budding mechanism controlled by Rab11-FIP2","volume":"105","author":"Utley","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126427","article-title":"A multivalent RSV vaccine based on the modified vaccinia ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study","volume":"42","author":"Jordan","year":"2024","journal-title":"Vaccine"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005486","article-title":"A numerically subdominant CD8 T cell response to matrix protein of respiratory syncytial virus controls infection with limited immunopathology","volume":"12","author":"Liu","year":"2016","journal-title":"PloS Pathog"},{"key":"B107","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/infdis\/jiad108","article-title":"Reduced respiratory syncytial virus load, symptoms, and infections: A human challenge trial of MVA-BN-RSV vaccine","volume":"228","author":"Jordan","year":"2023","journal-title":"J Infect Dis"},{"key":"B108","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41541-023-00734-7","article-title":"The road to approved vaccines for respiratory syncytial virus","volume":"8","author":"Ruckwardt","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated Vaccine12","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev-med-121217-094234","article-title":"Structure-based vaccine antigen design","volume":"70","author":"Graham","year":"2019","journal-title":"Annu Rev Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/srep34108","article-title":"Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus","volume":"6","author":"Killikelly","year":"2016","journal-title":"Sci Rep"},{"key":"B112","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nm.1894","article-title":"Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease","volume":"15","author":"Delgado","year":"2009","journal-title":"Nat Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020781","article-title":"A role for immune complexes in enhanced respiratory syncytial virus disease","volume":"196","author":"Polack","year":"2002","journal-title":"J Exp Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2893","article-title":"Structural vaccinology starts to deliver","volume":"10","author":"Dormitzer","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"key":"B119","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.immuni.2021.03.004","article-title":"Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses","volume":"54","author":"Mukhamedova","year":"2021","journal-title":"Immunity"},{"key":"B120","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s44298-025-00119-8","article-title":"A single amino acid mutation alters multiple neutralization epitopes in the respiratory syncytial virus fusion glycoprotein","volume":"3","author":"Oraby","year":"2025","journal-title":"NPJ Viruses"},{"key":"B121","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1038\/s41598-019-40387-y","article-title":"Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015-17","volume":"9","author":"Bin Lu","year":"2019","journal-title":"Sci Rep"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2216358","article-title":"The journey to RSV vaccines - heralding an era of structure-based design","volume":"388","author":"Graham","year":"2023","journal-title":"N Engl J Med"},{"key":"B123","article-title":"Evolutionary-scale prediction of atomic-level protein structure with a language model","volume":"379","author":"Lin","year":""},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06832-9","article-title":"Predicting multiple conformations via sequence clustering and AlphaFold2","volume":"625","author":"Wayment-Steele","year":"2024","journal-title":"Nature"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08416-7","article-title":"Addendum: Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"636","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1101\/2024.11.05.622169","article-title":"PLM-interact: Extending protein language models to predict protein-protein interactions","volume":"16","author":"Liu","year":"2024"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1101\/2025.03.09.642188","article-title":"Learning the language of protein-protein interactions","author":"Ullanat","year":"2025"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaf055","article-title":"Advances of computational methods enhance the development of multi-epitope vaccines","volume":"26","author":"Wei","year":"2025","journal-title":"Brief Bioinform"},{"key":"B129","doi-asserted-by":"publisher","first-page":"8243","DOI":"10.1038\/s41598-023-34863-9","article-title":"A state-of-the-art methodology for high-throughput in silico vaccine discovery against protozoan parasites and exemplified with discovered candidates for Toxoplasma gondii","volume":"13","author":"Goodswen","year":"2023","journal-title":"Sci Rep"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4497","article-title":"BepiPred-3.0: Improved B-cell epitope prediction using protein language models","volume":"31","author":"Clifford","year":"2022","journal-title":"Protein Sci"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1463931","article-title":"Integrating machine learning to advance epitope mapping","volume":"15","author":"Grewal","year":"2024","journal-title":"Front Immunol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2024.08.011","article-title":"Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged \u226560 years: A phase 1, randomized, observer-blind, placebo-controlled trial","volume":"62","author":"Fitz-Patrick","year":"2024","journal-title":"Respir Investig"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16077","article-title":"Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: Applications of reverse genetics","volume":"110","author":"Murphy","year":"2002","journal-title":"J Clin Invest"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy040","article-title":"Live-attenuated respiratory syncytial virus vaccine candidate with deletion of RNA synthesis regulatory protein M2-2 is highly immunogenic in children","volume":"217","author":"McFarland","year":"2018","journal-title":"J Infect Dis"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines14020186","article-title":"Comparative evaluation of mucosal adjuvants for intranasal immunization with a recombinant RSV prefusion F protein","volume":"14","author":"Hu","year":"2026","journal-title":"Vaccines (Basel)"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.4.6.861","article-title":"Viral vectors for inducing CD8+ T cell responses","volume":"4","author":"Truckenmiller","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.11","article-title":"Small hydrophobic protein of respiratory syncytial virus as a novel vaccine antigen","volume":"7","author":"Schepens","year":"2015","journal-title":"Immunotherapy"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy177","article-title":"A respiratory syncytial virus vaccine based on the small hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: A first-in-humans study","volume":"218","author":"Langley","year":"2018","journal-title":"J Infect Dis"},{"key":"B140","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1542\/peds.2010-1722C","article-title":"Integrating safety and efficacy evaluation throughout vaccine research and development","volume":"127","author":"Curlin","year":"2011","journal-title":"Pediatrics"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.932408","article-title":"Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development","volume":"13","author":"Bigay","year":"2022","journal-title":"Front Microbiol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.5812\/ijpr-150510","article-title":"Advancements and applications of artificial intelligence in pharmaceutical sciences: A comprehensive review","volume":"23","author":"Mottaghi-Dastjerdi","year":"2024","journal-title":"Iran J Pharm Res"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2026.102498","article-title":"Immunoinformatic-driven design of a multi-epitope vaccine against helicobacter pylori","volume":"45","author":"Rahimi-Farsi","year":"2026","journal-title":"Biochem Biophys Rep"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1042997","article-title":"Immunoinformatic-based design of immune-boosting multiepitope subunit vaccines against monkeypox virus and validation through molecular dynamics and immune simulation","volume":"13","author":"Suleman","year":"2022","journal-title":"Front Immunol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2024.2398171","article-title":"Designing a multi-epitope subunit vaccine against orf virus using molecular docking and molecular dynamics","volume":"15","author":"Pang","year":"2024","journal-title":"Virulence"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawai","year":""},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1682649","article-title":"Role of toll-like receptors in pulmonary immunity: Mechanisms and therapeutic implications","volume":"16","author":"Qu","year":"2025","journal-title":"Front Immunol"},{"key":"B149","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-0716-1892-9_1","article-title":"Artificial intelligence for vaccine design","volume-title":"Vaccine Design","author":"McCaffrey","year":"2022"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3390\/v16060821","article-title":"Respiratory syncytial virus vaccine design using structure-based machine-learning models","volume":"16","author":"McCarty","year":"2024","journal-title":"Viruses"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2023.03.002","article-title":"Leveraging deep learning to improve vaccine design","volume":"44","author":"Hederman","year":"2023","journal-title":"Trends Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2026.01.031","article-title":"Highly efficient and durable Th1-biased protective immunity from a novel mRNA vaccine against RSV via AI-assisted antigen screening","volume":"34","author":"Dong","year":"2026","journal-title":"Mol Ther"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S387479","article-title":"Immunity cell responses to RSV and the role of antiviral inhibitors: A systematic review","volume":"15","author":"Churiso","year":"2022","journal-title":"Infect Drug Resist"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.08.023","article-title":"Formulation of the prefusion RSV F protein with a Th1\/TH2-balanced adjuvant provides complete protection without TH2-skewed immunity in RSV-experienced young mice","volume":"38","author":"Kosanovich","year":"2020","journal-title":"Vaccine"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1025341","article-title":"Prior respiratory syncytial virus infection reduces vaccine-mediated TH2-skewed immunity, but retains enhanced RSV F-specific CD8 T cell responses elicited by a Th1-skewing vaccine formulation","volume":"13","author":"Eichinger","year":"2022","journal-title":"Front Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.3.541-555.2005","article-title":"Immune responses and disease enhancement during respiratory syncytial virus infection","volume":"18","author":"Openshaw","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.08.026","article-title":"Age-related differences in immunological responses to SARS-CoV-2","volume":"8","author":"Wong","year":"2020","journal-title":"J Allergy Clin Immunology: In Pract"},{"key":"B158","doi-asserted-by":"publisher","first-page":"230266","DOI":"10.1183\/16000617.0266-2023","article-title":"Diverging patterns in innate immunity against respiratory viruses during a lifetime: Lessons from the young and the old","volume":"33","author":"Smits","year":"2024","journal-title":"Eur Respir Rev"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901481","article-title":"Neonatal innate TLR-mediated responses are distinct from those of adults","volume":"183","author":"Kollmann","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.08.007","article-title":"Immunological lessons from respiratory syncytial virus vaccine development","volume":"51","author":"Ruckwardt","year":"2019","journal-title":"Immunity"},{"key":"B161","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12979-019-0164-9","article-title":"Immunosenescence and human vaccine immune responses","volume":"16","author":"Crooke","year":"2019","journal-title":"Immun Ageing"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3RI0716-335R","article-title":"Human T cell immunosenescence and inflammation in aging","volume":"102","author":"Bektas","year":"2017","journal-title":"J Leukocyte Biol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2019.103998","article-title":"Aging and influenza vaccine-induced immunity","volume":"348","author":"Dugan","year":"2020","journal-title":"Cell Immunol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0050-3","article-title":"Rethinking drug design in the artificial intelligence era","volume":"19","author":"Schneider","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151960","article-title":"Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design","volume":"213","author":"Rappuoli","year":"2016","journal-title":"J Exp Med"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2007.08383","article-title":"Deep learning in protein structural modeling and design","author":"Gao","year":"2020"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3389\/fbinf.2025.1580967","article-title":"Design of cross-reactive antigens with machine learning and high-throughput experimental evaluation","volume":"5","author":"Chesterman","year":"2025","journal-title":"Front Bioinf"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade6422","article-title":"Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine","volume":"15","author":"Che","year":"2023","journal-title":"Sci Transl Med"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202511.0078.v1","article-title":"From silicon to serum: The critical path of validating computational predictions in modern vaccinology","author":"Zhang","year":"2025"},{"key":"B170","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41541-025-01258-y","article-title":"AI-driven epitope prediction: A systematic review, comparative analysis, and practical guide for vaccine development","volume":"10","author":"Villanueva-Flores","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-021-01100-y","article-title":"Low-N protein engineering with data-efficient deep learning","volume":"18","author":"Biswas","year":"2021","journal-title":"Nat Methods"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.11.247072","article-title":"Learning with uncertainty for biological discovery and design","author":"Hie","year":""},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.03.109","article-title":"Advances in RSV vaccine research and development \u2013 a global agenda","volume":"34","author":"Higgins","year":"2016","journal-title":"Vaccine"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1406929","article-title":"Systematic computer-aided disulfide design as a general strategy to stabilize prefusion class I fusion proteins","volume":"15","author":"Gonzalez","year":"2024","journal-title":"Front Immunol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.1456","article-title":"Viral membrane fusion","volume":"15","author":"Harrison","year":"2008","journal-title":"Nat Struct Mol Biol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix503","article-title":"An adjuvanted, postfusion F protein\u2013based vaccine did not prevent respiratory syncytial virus illness in older adults","volume":"216","author":"Falloon","year":"2017","journal-title":"J Infect Dis"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2017.03.012","article-title":"Vaccine development for respiratory syncytial virus","volume":"23","author":"Graham","year":"2017","journal-title":"Curr Opin Virol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3390\/v13071320","article-title":"Targeting viral surface proteins through structure-based design","volume":"13","author":"Narkhede","year":"2021","journal-title":"Viruses"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.30.125484","article-title":"Structure-based design of prefusion-stabilized SARS-coV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"bioRxiv"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.576622","article-title":"The SARS-coV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens","volume":"11","author":"Duan","year":"2020","journal-title":"Front Immunol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.11.944462","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"bioRxiv"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"key":"B183","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2409566122","article-title":"From sequence to scaffold: Computational design of protein nanoparticle vaccines from AlphaFold2-predicted building blocks","volume":"122","author":"Haas","year":"2025","journal-title":"Proc Natl Acad Sci"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3390\/v14061305","article-title":"A hemagglutinin stem vaccine designed rationally by AlphaFold2 confers broad protection against influenza B infection","volume":"14","author":"Zeng","year":"2022","journal-title":"Viruses"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat Med"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1402766111","article-title":"Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection","volume":"111","author":"Mallajosyula","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2406.05540","article-title":"A fine-tuning dataset and benchmark for large language models for protein understanding","author":"Shen","year":"2024"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.666756","article-title":"Glycans in virus-host interactions: a structural perspective","volume":"8","author":"Miller","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B191","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1038\/s41467-020-16567-0","article-title":"Vulnerabilities in coronavirus glycan shields despite extensive glycosylation","volume":"11","author":"Watanabe","year":"2020","journal-title":"Nat Commun"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jpcb.0c11516","article-title":"Glycan cluster shielding and antibody epitopes on Lassa virus envelop protein","volume":"125","author":"Re","year":"2021","journal-title":"J Phys Chem B"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-022-00849-w","article-title":"A structural biology community assessment of AlphaFold2 applications","volume":"29","author":"Akdel","year":"2022","journal-title":"Nat Struct Mol Biol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btac202","article-title":"Impact of protein conformational diversity on AlphaFold predictions","volume":"38","author":"Salda\u00f1o","year":"2022","journal-title":"Bioinformatics"},{"key":"B196","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1084\/jem.20182160","article-title":"Vaccines: an achievement of civilization, a human right, our health insurance for the future","volume":"216","author":"Rappuoli","year":"2019","journal-title":"J Exp Med"},{"key":"B197","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13073-015-0243-2","article-title":"Practical guidelines for B-cell receptor repertoire sequencing analysis","volume":"7","author":"Yaari","year":"2015","journal-title":"Genome Med"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.70157","article-title":"SARS\u2010CoV\u20102 variants and immune evasion: mapping the future of vaccine design","volume":"36","author":"Uzer","year":"2026","journal-title":"Rev Med Virol"},{"key":"B199","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1128\/CMR.00090-16","article-title":"The human immune response to respiratory syncytial virus infection","volume":"30","author":"Russell","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060624","article-title":"Considerations for a respiratory syncytial virus vaccine targeting an elderly population","volume":"9","author":"Stephens","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2019.05.012","article-title":"Exploitation of glycosylation in enveloped virus pathobiology","volume":"1863","author":"Watanabe","year":"2019","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-023-02087-4","article-title":"AlphaFold predictions are valuable hypotheses and accelerate but do not replace experimental structure determination","volume":"21","author":"Terwilliger","year":"2024","journal-title":"Nat Methods"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1862216\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:31:45Z","timestamp":1782102705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1862216\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":202,"alternative-id":["10.3389\/fimmu.2026.1862216"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1862216","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1862216"}}